Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, August 28, 2025
Piramal Pharma Limited (PPL) published its fourth annual Sustainability Report for FY2025, documenting performance and progress under the theme “Innovating Responsibly. Growing Sustainably.”
read more
Hongene Biotech Corporation entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and exNA-modified oligonucleotides for research use.
read more
Scenic Biotech announced a license and research agreement with Alnylam Pharma to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics.
read more
Cambrex announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts to further support the development and manufacturing of peptide therapies.
read more
PCM Trials, and its subsidiaries EmVenio Research and Clinical Trial Service, are aligning under a single name – EmVenio Clinical Research. This consolidation brings together each company’s strengths under one entity to offer sponsors and contract ...
read more
Thursday, August 21, 2025
Piramal Pharma Solutions and NewAmsterdam Pharma Company announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product ...
read more
Wednesday, August 20, 2025
The Parkinson's Foundation announced the launch of a new pilot program, PD Trial Navigator, which will help fulfill a central goal of the ongoing PD GENEration study to accelerate genetic-focused clinical trials. PD Trial Navigators will meet with ...
read more
Wednesday, August 20, 2025
ChemPartner announced its strategic expansion in the U.S. with the upcoming opening of the ChemPartner Boston Center of Excellence in Watertown, MA. The new R&D site will commence operations on September 10, 2025, providing discovery and preclinical ...
read more
Wednesday, August 20, 2025
Headlands Research announced the opening of Headlands Research Twin Cities (HRTC), its 23rd fully owned site. Strategically situated in the Minneapolis–St. Paul metro area, the new center offers pharmaceutical sponsors and CROs rapid, single-contract...
read more
Made Scientific recently held a ribbon-cutting ceremony to commemorate the grand opening of its new 60,000 sq. ft. GMP manufacturing facility and headquarters in Princeton, New Jersey.
read more
Upperton Pharma Solutions has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford. The funding supports the development of an oral formulation for Adenovirus-vectored ...
read more
IQVIA and Veeva Systems announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings ...
read more
Avixgen, a subsidiary of Dx&Vx, has signed a licensing-out agreement worth approximately $360M with a U.S. biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Peptide). Avixgen is a drug development ...
read more
Thursday, August 14, 2025
THL Partners, a private equity firm investing in middle market growth companies, announced the entry into a definitive agreement to acquire Headlands Research, a multinational network of clinical trial sites, from funds managed by global investment ...
read more
Thursday, August 14, 2025
Avista Therapeutics and Forge Biologics announced a strategic partnership to advance the development and manufacturing of AVST-101, Avista’s lead gene therapy candidate targeting X-linked retinoschisis (XLRS), a serious inherited retinal disease.
read more